Ahmadreza Karimianpour1, Patrick Badertscher1, Joshua Payne1, Michael Field1, Michael R Gold1, Jeffrey R Winterfield2. 1. Section of Clinical Cardiac Electrophysiology, Division of Cardiology, Department of Medicine, Medical University of South Carolina, 171 Ashley Ave, Charleston, SC, 29425, USA. 2. Section of Clinical Cardiac Electrophysiology, Division of Cardiology, Department of Medicine, Medical University of South Carolina, 171 Ashley Ave, Charleston, SC, 29425, USA. winterfj@musc.edu.
Abstract
BACKGROUND: Ventricular tachycardia (VT) ablation of mid- or epicardial substrate is difficult and requires a creative approach in patients with a history of coronary bypass that precludes percutaneous epicardial catheter manipulation. The coronary venous system (CVS) provides limited access to the epicardial surface of the heart. The objective of this study is to assess the feasibility, safety, and efficacy of epicardial mapping and ablation of VT substrates from the CVS in patients with history of coronary bypass. METHODS: Patients undergoing VT ablation at our institution were retrospectively reviewed. Those who had basal to mid ventricular substrate based on computed tomography imaging and history of coronary bypass were included. Endocardial and CVS mapping and ablation was performed in standard fashion using 3D electroanatomic mapping. The primary endpoint was defined as VT circuit elimination, termination, non-inducibility, or perturbation of the circuit. RESULTS: Of 192 consecutive VT ablations from 2017 to 2020, 35 (18%) had a history of coronary bypass and basal to the mid-ventricular substrate by imaging. There were no significant characteristic differences between the endocardial only (n = 19) vs endocardial + CVS (n = 16) groups. In 14 (88%) of patients undergoing CVS mapping, the VT circuit was identified to be within access from the epicardial surface. Ablation was attempted in 8 (57%) of these patients, and the primary endpoint was reached in 88% of those undergoing CVS ablation. There were no complications related to CVS ablation. CONCLUSION: Mapping and ablation of mid- or epicardial VT circuits from the CVS branches are feasible and safe and may be helpful in the treatment of VT in patients who are otherwise not candidates for percutaneous epicardial ablation.
BACKGROUND: Ventricular tachycardia (VT) ablation of mid- or epicardial substrate is difficult and requires a creative approach in patients with a history of coronary bypass that precludes percutaneous epicardial catheter manipulation. The coronary venous system (CVS) provides limited access to the epicardial surface of the heart. The objective of this study is to assess the feasibility, safety, and efficacy of epicardial mapping and ablation of VT substrates from the CVS in patients with history of coronary bypass. METHODS: Patients undergoing VT ablation at our institution were retrospectively reviewed. Those who had basal to mid ventricular substrate based on computed tomography imaging and history of coronary bypass were included. Endocardial and CVS mapping and ablation was performed in standard fashion using 3D electroanatomic mapping. The primary endpoint was defined as VT circuit elimination, termination, non-inducibility, or perturbation of the circuit. RESULTS: Of 192 consecutive VT ablations from 2017 to 2020, 35 (18%) had a history of coronary bypass and basal to the mid-ventricular substrate by imaging. There were no significant characteristic differences between the endocardial only (n = 19) vs endocardial + CVS (n = 16) groups. In 14 (88%) of patients undergoing CVS mapping, the VT circuit was identified to be within access from the epicardial surface. Ablation was attempted in 8 (57%) of these patients, and the primary endpoint was reached in 88% of those undergoing CVS ablation. There were no complications related to CVS ablation. CONCLUSION: Mapping and ablation of mid- or epicardial VT circuits from the CVS branches are feasible and safe and may be helpful in the treatment of VT in patients who are otherwise not candidates for percutaneous epicardial ablation.
Authors: Ioan Liuba; David S Frankel; Michael P Riley; Mathew D Hutchinson; David Lin; Fermin C Garcia; David J Callans; Gregory E Supple; Sanjay Dixit; Rupa Bala; Fabien Squara; Erica S Zado; Francis E Marchlinski Journal: Heart Rhythm Date: 2014-02-19 Impact factor: 6.343
Authors: Martin Aguilar; Usha B Tedrow; Wendy S Tzou; Roderick Tung; David S Frankel; Pasquale Santangeli; Marmar Vaseghi; T Jared Bunch; Luigi Di Biase; Venkatakrishna N Tholakanahalli; Dhanunjaya Lakkireddy; Timm Dickfeld; J Peter Weiss; Nilesh Mathuria; Pasquale Vergara; Shiro Nakahara; Jason S Bradfield; J David Burkhardt; William G Stevenson; David J Callans; Paolo Della Bella; Andrea Natale; Kalyanam Shivkumar; Francis E Marchlinski; William H Sauer Journal: J Cardiovasc Electrophysiol Date: 2021-01-24
Authors: Cory M Tschabrunn; Haris M Haqqani; Joshua M Cooper; Sanjay Dixit; Fermin C Garcia; Edward P Gerstenfeld; David J Callans; Erica S Zado; Francis E Marchlinski Journal: Heart Rhythm Date: 2012-10-09 Impact factor: 6.343
Authors: Divyang Patel; Vic Hasselblad; Kevin P Jackson; Sean D Pokorney; James P Daubert; Sana M Al-Khatib Journal: J Interv Card Electrophysiol Date: 2015-12-22 Impact factor: 1.900
Authors: Ammar M Killu; Elisa Ebrille; Samuel J Asirvatham; Thomas M Munger; Christopher J McLeod; Douglas L Packer; Paul A Friedman; Siva K Mulpuru Journal: Circ Arrhythm Electrophysiol Date: 2015-01-09